Choice of designs and doses for early phase trials
- 9 February 2004
- journal article
- review article
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 18 (3) , 373-378
- https://doi.org/10.1111/j.1472-8206.2004.00226.x
Abstract
This paper reviews state-of-art statistical designs for dose-escalation procedures in first-into-man studies. The main focus will be on studies in oncology, as most statistical procedures for phase I trials have been proposed in this context. Extensions to situations such as the observation of bivariate outcomes and healthy volunteer studies are also discussed. The number of dose levels and cohort sizes used in early phase trials are considered. Finally, this paper raises some practical issues for dose-escalation procedures.Keywords
This publication has 34 references indexed in Scilit:
- Practical Implementation of Bayesian Dose-Escalation ProceduresDrug Information Journal, 2003
- Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteersBiostatistics, 2001
- Miscellanea. A stopping rule for the continual reassessment methodBiometrika, 1998
- Bayesian decision procedures based on logistic regression models for dose-finding studiesJournal of Biopharmaceutical Statistics, 1998
- Some practical improvements in the continual reassessment method for phase I studiesStatistics in Medicine, 1995
- INFLUENCE OF CONFOUNDING FACTORS ON DESIGNS FOR DOSE–EFFECT RELATIONSHIP ESTIMATESStatistics in Medicine, 1995
- A comparison of two phase I trial designsStatistics in Medicine, 1994
- A Method for Obtaining and Analyzing Sensitivity DataJournal of the American Statistical Association, 1948